These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35512733)

  • 1. Susceptibility of
    Schaumburg F; Idelevich EA; Mellmann A; Kahl BC
    Microb Drug Resist; 2022 May; 28(5):545-550. PubMed ID: 35512733
    [No Abstract]   [Full Text] [Related]  

  • 2.
    Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D
    Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964
    [TBL] [Abstract][Full Text] [Related]  

  • 3. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant
    Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM
    J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overcoming an Extremely Drug Resistant (XDR) Pathogen: Avibactam Restores Susceptibility to Ceftazidime for Burkholderia cepacia Complex Isolates from Cystic Fibrosis Patients.
    Papp-Wallace KM; Becka SA; Zeiser ET; Ohuchi N; Mojica MF; Gatta JA; Falleni M; Tosi D; Borghi E; Winkler ML; Wilson BM; LiPuma JJ; Nukaga M; Bonomo RA
    ACS Infect Dis; 2017 Jul; 3(7):502-511. PubMed ID: 28264560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kazmierczak KM; Bradford PA; Stone GG; de Jonge BLM; Sahm DF
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249690
    [No Abstract]   [Full Text] [Related]  

  • 7. Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.
    Dupont H; Gaillot O; Goetgheluck AS; Plassart C; Emond JP; Lecuru M; Gaillard N; Derdouri S; Lemaire B; Girard de Courtilles M; Cattoir V; Mammeri H
    Antimicrob Agents Chemother; 2016 Jan; 60(1):215-21. PubMed ID: 26482307
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-vitro susceptibility testing methods for the combination of ceftazidime-avibactam with aztreonam in metallobeta-lactamase producing organisms: Role of combination drugs in antibiotic resistance era.
    Sreenivasan P; Sharma B; Kaur S; Rana S; Biswal M; Ray P; Angrup A
    J Antibiot (Tokyo); 2022 Aug; 75(8):454-462. PubMed ID: 35715617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in ceftazidime-avibactam activity against multidrug-resistant organisms recovered from respiratory samples of cystic fibrosis patients.
    Farfour E; Trochu E; Devin C; Cardot Martin E; Limousin L; Roux A; Picard C; Jolly E; Vasse M; Lesprit P
    Transpl Infect Dis; 2018 Oct; 20(5):e12955. PubMed ID: 29896802
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series.
    Spoletini G; Etherington C; Shaw N; Clifton IJ; Denton M; Whitaker P; Peckham DG
    J Antimicrob Chemother; 2019 May; 74(5):1425-1429. PubMed ID: 30649419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aztreonam-Avibactam Susceptibility Testing Program for Metallo-Beta-Lactamase-Producing
    Bhatnagar A; Boyd S; Sabour S; Bodnar J; Nazarian E; Peinovich N; Wagner C; Craft B; Snippes Vagnone P; Simpson J; Stone VN; Therrien M; Bateman A; Lower D; Huang JY; Gumbis S; Lonsway D; Lutgring JD; Karlsson M; Brown AC
    Antimicrob Agents Chemother; 2021 Jul; 65(8):e0048621. PubMed ID: 34060895
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro efficacy of ceftazidime-avibactam, aztreonam-avibactam and other rescue antibiotics against carbapenem-resistant Enterobacterales from the Arabian Peninsula.
    Sonnevend Á; Ghazawi A; Darwish D; Barathan G; Hashmey R; Ashraf T; Rizvi TA; Pál T
    Int J Infect Dis; 2020 Oct; 99():253-259. PubMed ID: 32738488
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of aztreonam in combination with ceftazidime-avibactam against serine- and metallo-β-lactamase-producing Pseudomonas aeruginosa.
    Lee M; Abbey T; Biagi M; Wenzler E
    Diagn Microbiol Infect Dis; 2021 Jan; 99(1):115227. PubMed ID: 33086177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time-Kill Evaluation of Antibiotic Combinations Containing Ceftazidime-Avibactam against Extensively Drug-Resistant Pseudomonas aeruginosa and Their Potential Role against Ceftazidime-Avibactam-Resistant Isolates.
    Montero MM; Domene Ochoa S; López-Causapé C; Luque S; Sorlí L; Campillo N; López Montesinos I; Padilla E; Prim N; Angulo-Brunet A; Grau S; Oliver A; Horcajada JP
    Microbiol Spectr; 2021 Sep; 9(1):e0058521. PubMed ID: 34319141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Looking for
    Ranieri EM; Denicolò S; Stolfa S; Dalfino L; Bavaro DF; Saracino A; Ronga L; Del Prete R; Mosca A
    J Chemother; 2023 Nov; 35(7):610-613. PubMed ID: 37615040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland.
    Lupo A; Isis E; Tinguely R; Endimiani A
    New Microbiol; 2015 Apr; 38(2):281-8. PubMed ID: 25938755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can Ceftazidime-Avibactam and Aztreonam Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in Enterobacteriaceae?
    Marshall S; Hujer AM; Rojas LJ; Papp-Wallace KM; Humphries RM; Spellberg B; Hujer KM; Marshall EK; Rudin SD; Perez F; Wilson BM; Wasserman RB; Chikowski L; Paterson DL; Vila AJ; van Duin D; Kreiswirth BN; Chambers HF; Fowler VG; Jacobs MR; Pulse ME; Weiss WJ; Bonomo RA
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lung transplantation in two cystic fibrosis patients infected with previously pandrug-resistant Burkholderia cepacia complex treated with ceftazidime-avibactam.
    Los-Arcos I; Len O; Martín-Gómez MT; González-López JJ; Saéz-Giménez B; Deu M; Nuvials X; Ferrer R; Román A; Gavaldà J
    Infection; 2019 Apr; 47(2):289-292. PubMed ID: 30565008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the in vitro impact of ceftazidime on aztreonam/avibactam susceptibility testing for highly resistant MBL-producing Enterobacterales.
    Bhatnagar A; Ransom EM; Machado MJ; Boyd S; Reese N; Anderson K; Lonsway D; Elkins CA; Rasheed JK; Patel JB; Karlsson M; Brown AC; Lutgring JD
    J Antimicrob Chemother; 2021 Mar; 76(4):979-983. PubMed ID: 33367916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceftazidime plasma concentration in a patient with cystic fibrosis treated with ceftazidime/avibactam plus trimethoprim/sulfametoxazole for
    Saffioti C; Barco S; Cangemi G; Mesini A; Casciaro R; Cresta F; Castellani C; Bandettini R; Morelli P; Castagnola E
    J Chemother; 2019; 31(7-8):436-438. PubMed ID: 31583970
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.